Trial Profile

A Phase 1b/2, Open-label Dose Escalation With Expansion Study of GB5121 in Adult Patients With Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma, With a Phase 2 Open-label Single Dose Level Study of GB5121 in Adult Patients With Relapsed/ Refractory Primary Central Nervous System Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GB 5121 (Primary)
Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Intraocular lymphoma; Lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms STAR CNS
Sponsors Gossamer Bio

12 Jun 2023 Status changed from suspended to discontinued as per Sponsor decision.
30 May 2023 This trial has been discontinued in Sweden (End Date: 11 May 2023), according to European Clinical Trials Database record.
18 Apr 2023 The trial has been discontinued in Netherlands and Spain, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com